Gapping up
In reaction to strong earnings/guidance:
- SIEN +21.4%, FSLY +19.7%, STMP +19.4%, AAXN +17.6%, PAR +14.3%, EB +12.3%, ZG +11.3%, SWCH +10.8%, QNST +10.1% (also retains Goldman Sachs for review of strategic alternatives), AMPH +9.2%, PLNT +9.1% (also appoints Jeremy Tucker as Chief Marketing Officer, effective November 20), CORT +8.7%, YELP +8.6%, VSAT +8.6%, MTW +8.3%, GH +8.3%, FARM +7.7% (also discloses CFO change), GPRO +6.9%, LGF.A +6.4%, MIME +5.8%, DIS +5.7%, UEPS +5.2%, BKNG +4.8%, SWAV +4.3%, SGMS +4.3%, NCR +4.1%, CUTR +4.1%, MNST +4%, TROX +3.3%, AL +3%, AIRG +2.9%, ZIOP +2.7%, NET +2.6%, AMH +2.5%, REV +2.3%, RVLV +2.2%, CYRX +2.2%, CDAY +1.9% (CFO Arthur Gitajn to retire), ENB +1.6%, DBX +1.4%, NLOK +1.4%, AMCR +1.3%, AMBC +1.2%, WPRT +1%, HMC +1%
Other news:
- CFMS +15.7% (announces FDA clearance of next generation Conformis Hip System)
- IOVA +11.3% (presents new data from Cohort 2 of the ongoing Phase 2 lifileucel metastatic melanoma study)
- NK +10.1% (announces presentation of results from Phase 2 trial of natural killer cell-based therapeutic in metastatic Merkel cell carcinoma)
- PRTY +10% (modestly rebounding from yesterday's 67% decline)
- WKHS +4.2% (enters into intellectual property licensing agreement with Lordstown Motors Corp)
- EXEL +3.8% (collaborator Daiichi Sankyo reports positive results from Phase 3 pivotal trial of Esaxerenone)
- AIMT +2.2% (announces results from new analysis showing consistent efficacy and safety with AR101 across phase 3 PALISADE and ARTEMIS trials)
- MSG +0.9% (Madison Square Garden announces update regarding potential spin-off transaction; now pursuing full spin-off of entertainment businesses from sports businesses)
Analyst comments:
- TEX +3.8% (upgraded to Buy from Neutral at Goldman and added to Conviction Buy List)
- FL +2.2% (upgraded to Positive from Neutral at Susquehanna)
- ZIXI +1% (initiated with Outperform at Wedbush; tgt $10)
- MCD +0.9% (upgraded to Buy from Neutral at Longbow).
